Philogen Approves 2025 Results, €0.70 Dividend and New Share Buyback Mandate

Philogen SpA ( (IT:PHIL) ) has issued an announcement.

Philogen’s 2026 ordinary shareholders’ meeting approved the 2025 separate financial statements and directed the full-year net profit of €229.68 million, along with portions of retained earnings and share premium, into a non-distributable reserve linked to equity-accounted investments. Shareholders also cleared a cash dividend of €0.70 per share, to be paid from past profit reserves to all dividend-entitled ordinary and class B shares, excluding any treasury stock on the record date.

The meeting backed the company’s 2026 remuneration policy for directors, top management and statutory auditors, and endorsed the report summarizing 2025 compensation, reinforcing governance and pay transparency. Investors further authorized a new 18‑month buyback program allowing Philogen to purchase up to 5% of its share capital, and to dispose of treasury shares without time limits, giving the company added flexibility in capital management and potential support for future strategic initiatives.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR34.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

More about Philogen SpA

Philogen is an Italian-Swiss biotechnology group focused on discovering and developing targeted anti-cancer drugs for diseases with high mortality rates. The company uses proprietary tumor- and vascular-targeting technologies, based on human monoclonal antibodies and small molecules, to selectively deliver potent therapeutic agents to tumors while sparing healthy tissues, supported by an extensive patent portfolio.

Average Trading Volume: 18,461

Technical Sentiment Signal: Hold

Current Market Cap: €608.3M

For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.